Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles

Area of Science:

• Biotechnology
• Nanomedicine
• Molecular Biology

Background:

• Clinical applications of nanoparticle drug delivery systems face challenges including size homogeneity, manufacturing reproducibility, liver uptake, toxicity, and poor tumor selectivity.
• Current nanoparticle systems often struggle to achieve efficient and targeted delivery to tumor sites.

Purpose of the Study:

• To develop a novel, self-assembling nanoparticle system for targeted tumor delivery with innate biological activity.
• To investigate the potential of synthetic transmembrane protein analogs as uniform, biologically active nanoparticles.
• To evaluate the efficacy of these nanoparticles in inhibiting tumor metastasis and their capacity for drug encapsulation.

Main Methods:

• Synthetic analogs of transmembrane domains of membrane proteins were designed and modified.
• Self-assembly properties and structural transitions (beta-hairpin to alpha-helix) of the peptides were studied in aqueous solutions and upon cell membrane interaction.
• A specific peptide analog targeting CXCR4 was synthesized and its in vitro and in vivo effects on CXCR4 function and tumor metastasis were assessed.
• The ability of the nanoparticles to encapsulate hydrophobic drugs was evaluated.

Main Results:

• Modified synthetic transmembrane protein analogs self-assembled into uniform spherical nanoparticles with innate biological activity.
• A 24-amino acid peptide analog of the CXCR4 transmembrane helix formed nanoparticles that inhibited CXCR4 function in vitro.
• These CXCR4-targeting nanoparticles demonstrated efficacy in hampering CXCR4-dependent tumor metastasis in vivo.
• The nanoparticles exhibited the capability to encapsulate hydrophobic drugs, suggesting potential for dual therapeutic action.

Conclusions:

• Self-assembling nanoparticles derived from synthetic transmembrane protein analogs represent a promising advancement in targeted drug delivery.
• These nanoparticles overcome limitations of traditional systems, offering improved homogeneity, potential for reduced toxicity, and enhanced tumor selectivity.
• The dual functionality of inhibiting tumor progression and delivering therapeutic agents positions these nanoparticles as a versatile platform for cancer therapy.